Koinfekcija: Primarna varičela i COVID-19- Prikaz slučaja
Sažetak
Uvod: Primarna varičela se obično javlja u detinjstvu i generalno je samoograničavajuća bolest. Kod odraslih i imunodeficijentnih osoba može imati ozbiljniji tok. Gojaznost je jedan od faktora rizika za teži oblik COVID-19 infekcije, koji može dovesti do imunosupresije i drugih sistemskih komplikacija. Ovaj prikaz slučaja ima za cilj da predstavi retku koinfekciju primarnom varičelom i COVID-19 kod odrasle osobe, da proceni uticaj ove koinfekcije na tok i težinu oba oboljenja kao i da naglasi značaj antivirusne terapije u lečenju oba oboljenja.
Prikaz slučaja: Prikazaćemo slučaj koinfekcije primarnom varičelom i COVID-19 kod žene starosti 34 godine sa postojećim problemom gajoznosti i koja je uspešno lečena oralnim aciklovirom i nirmatrelevir-ritonavirom bez razvoja značajnih komplikacija.
Zaključak: Trenutno ne postoji dovoljno dokaza da tvrdimo da koinfekcija primarnom varičelom i COVID-19 povećava šanse za teži oblik bilo koje od ovih infekcija. Uz efikasnu antivirusnu terapiju moguće je značajno smanjiti šanse za razviće težih formi obe infekcije, što bi lekari trebalo da imaju u vidu u slučaju koinfekcije sa ova dva virusna oboljenja i samim tim da reaguju pravovremeno.
Reference
1. WHO Director-General’s opening remarks at the media briefing on COVID19 -March 2020. https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020
2. Long B, Carius BM, Chavez S, Liang SY, Brady WJ, Koyfman A, et al. Clinical update on COVID-19 for the emergency clinician: Presentation and evaluation. Am J Emerg Med 2022; 54: 46-57.
3. Rahman S, Montero MTV, Rowe K, Kirton R, Kunik F Jr. Epidemiology, pathogenesis, clinical presentations, diagnosis and treatment of COVID-19: a review of current evidence. Expert Rev Clin Pharmacol 2021; 14: 601-21.
4. Sanyaolu A, Okorie C, Marinkovic A, Patidar R, Younis K, Desai P, et al. Comorbidity and its Impact on Patients with COVID-19. SN Compr Clin Med 2020; 2: 1069-76.
5. Alwarawrah Y, Kiernan K, MacIver NJ. Changes in Nutritional Status Impact Immune Cell Metabolism and Function. Front Immunol 2018;9:1055.
6. Huttunen R, Syrjänen J. Obesity and the risk and outcome of infection. Int J Obes (Lond). 2013; 37: 333-40.
7. Freer G, Pistello M. Varicella-zoster virus infection: natural history, clinical manifestations, immunity and current and future vaccination strategies. New Microbiol 2018; 41: 95-105.
8. Kennedy PGE, Gershon AA. Clinical Features of Varicella-Zoster Virus Infection. Viruses 2018; 10: 609.
9. Wang F, Nie J, Wang H, Zhao Q, Xiong Y, Deng L, et al. Characteristics of Peripheral Lymphocyte Subset Alteration in COVID-19 Pneumonia. J Infect Dis 2020; 221: 1762-69.
10. Zheng M, Gao Y, Wang G, Song G, Liu S, Sun D, et al. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cell Mol Immunol 2020; 17: 533-35.
11. Singh H, Kaur H, Singh K, Sen CK. Cutaneous Manifestations of COVID-19: A Systematic Review. Adv Wound Care (New Rochelle) 2021; 10: 51-80.
12. Tunbridge AJ, Breuer J, Jeffery KJ; British Infection Society. Chickenpox in adults - clinical management. J Infect 2008; 57: 95-102.
13. Gershon AA, Breuer J, Cohen JI, Cohrs RJ, Gershon MD, Gilden D, et al. Varicella zoster virus infection. Nat Rev Dis Primers 2015; 1: 15016.
14. Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis 2020; 71: 762-8.
15. Acharya D, Liu G, Gack MU. Dysregulation of type I interferon responses in COVID-19. Nat Rev Immunol 2020; 20: 397-8.
16. Popkin BM, Du S, Green WD, Beck MA, Algaith T, Herbst CH, et al. Individuals with obesity and COVID-19: A global perspective on the epidemiology and biological relationships. Obes Rev 2020; 21: e13128.
17. Bruno J, Ragozzino S, Quitt J, Siegemund M, Labhardt N. Severe acute respiratory syndrome coronavirus 2, primary varicella zoster virus coinfection, and a polymicrobial ventilator-associated tracheobronchitis in an adult immunocompetent male: a case report. J Med Case Rep 2022; 16: 45.
18. Loh J, Tham SM, Tambyah PA, Yan G, Lee CK, Chai LYA. Range of Varicella Zoster Co-Infections with COVID-19, Singapore. Infect Chemother 2021; 53: 391-4.
19. Lopez-Trujillo E, Rodriguez Mercader S, Güerri-Fernández R, Arrieta Aldea I, Pujol RM, Martin-Ezquerra G. Varicella complicated with pneumonia in a patient infected by COVID-19: the need to rule out other viral coinfections in SARS-CoV-2 patients with vesicular eruptions. Int J Dermatol 2021; 60: 886-8.
20. Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W, et al. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. N Engl J Med 2022; 386: 1397-1408.
21. US Food and Drug Administration. Fact sheet for healthcare providers: emergency authorization for Paxlovid. 2022. Available at: https://www.fda.gov/media/155050/download. Accessed 10 January 2023.
22. Andrei G, Snoeck R. Advances and Perspectives in the Management of Varicella-Zoster Virus Infections. Molecules 2021; 26: 1132.